UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 20, 2018

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

Massachusetts

 

0-17999

 

04-2726691

(State or other
jurisdiction of
incorporation)

 

(Commission File
Number)

 

(IRS Employer
Identification No.)

 

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 895-0600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is a an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

ITEM 5.02 — DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

 

(a) — (d)  Not applicable.

 

(e)  At the 2018 annual meeting of shareholders of ImmunoGen, Inc. (referred to as “our”) held on June 20, 2018 (the “2018 Annual Meeting”), our shareholders approved the ImmunoGen, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan (the “2018 Plan”) and the ImmunoGen, Inc. Employee Stock Purchase Plan (the “ESPP”).  Summaries of the material terms and conditions of the 2018 Plan and the ESPP are set forth in our definitive Proxy Statement dated April 30, 2018, filed with the Securities and Exchange Commission on April 30, 2018, under the captions “Approval of the 2018 Employee, Director and Consultant Equity Incentive (Notice Item 3)” and “Approval of the Employee Stock Purchase Plan (Notice Item 4),” respectively.  Such descriptions are incorporated herein by reference and are qualified in their entirety by reference to the full text of the 2018 Plan and the ESPP filed as Exhibits 10.1 and 10.6, respectively, to this current report on Form 8-K.

 

(f)  Not applicable.

 

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

 

As stated above, the 2018 Annual Meeting was held on June 20, 2018.  At the 2018 Annual Meeting, shareholders fixed the number of Directors constituting the full Board of Directors at seven.  The voting results were as follows:

 

For:

 

91,996,958

 

Against

 

69,622

 

Abstain

 

111,265

 

Broker Non-Votes

 

31,896,166

 

 

At the 2018 Annual Meeting, shareholders elected seven Directors as follows:

 

 

 

FOR

 

WITHHELD

 

BROKER NON-VOTES

 

Stephen C. McCluski

 

91,460,823

 

717,022

 

31,896,166

 

Richard J. Wallace

 

91,283,969

 

893,876

 

31,896,166

 

Mark Goldberg, MD

 

73,509,651

 

18,668,194

 

31,896,166

 

Dean J. Mitchell

 

81,436,371

 

10,741,474

 

31,896,166

 

Kristine Peterson

 

57,950,060

 

34,227,785

 

31,896,166

 

Mark J. Enyedy

 

91,699,299

 

478,546

 

31,896,166

 

Stuart A. Arbuckle

 

91,930,195

 

247,650

 

31,896,166

 

 

At the 2018 Annual Meeting, shareholders approved the 2018 Plan, which is referenced in Item 5.02 above, as follows:

 

2



 

For:

 

66,962,614

 

Against

 

25,081,333

 

Abstain

 

133,898

 

Broker Non-Votes

 

31,896,166

 

 

At the 2018 Annual Meeting, shareholders approved the ESPP, which is referenced in Item 5.02 above, as follows:

 

For:

 

71,913,571

 

Against

 

20,189,140

 

Abstain

 

75,134

 

Broker Non-Votes

 

31,896,166

 

 

At the 2018 Annual Meeting, shareholders voted to approve, on an advisory basis, the compensation paid to the our named executive officers, as described in our proxy statement (the “say-on-pay vote”) as follows:

 

For:

 

83,846,370

 

Against

 

8,163,331

 

Abstain

 

168,144

 

Broker Non-Votes

 

31,896,166

 

 

At the 2018 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018 as follows:

 

For:

 

123,405,942

 

Against

 

323,412

 

Abstain

 

344,657

 

Broker Non-Votes

 

0

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

(d): The following exhibits are being filed herewith:

 

Exhibit 
No.

 

Exhibit

 

 

 

10.1

 

2018 Employee, Director and Consultant Equity Incentive Plan

10.2

 

Form of Incentive Stock Option Agreement under the 2018 Employee, Director and Consultant Equity Incentive Plan

10.3

 

Form of Non-Qualified Stock Option Agreement for employees under the 2018 Employee, Director and Consultant Equity Incentive Plan

10.4

 

Form of Restricted Stock Unit Agreement under the 2018 Employee, Director and Consultant Equity Incentive Plan

10.5

 

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under the 2018 Employee, Director and Consultant Equity Incentive Plan

10.6

 

Form of Deferred Stock Unit Agreement for Non-Employee Directors under the 2018 Employee, Director and Consultant Equity Incentive Plan

10.7

 

Employee Stock Purchase Plan

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ImmunoGen, Inc.

 

(Registrant)

 

 

Date: June 22, 2018

/s/ David B. Johnston

 

 

 

David B. Johnston

 

Executive Vice President and Chief Financial Officer

 

4